Int J App Pharm, Vol 11, Issue 5, 2019, 317-323Original Article



Department of Pharmaceutics, Government College of Pharmacy, #P Kalinga Rao Road, Subbaiah Circle, Bengaluru, Karnataka, India
Email: [email protected]

Received: 25 Apr 2019, Revised and Accepted: 06 Aug 2019


Objective: A simple, economical, robust and stability-indicating reverse phase high performance liquid chromatography method was developed and validated for the quantification of ropinirole hydrochloride in API and tablets to achieve shorter retention time, to minimize human error by avoiding the use of buffers and weighing procedure and analyze more number of samples in shorter period of time with good accuracy.

Methods: The chromatographic conditions for separation of ropinirole hydrochloride was carried out using Gemini NX C18 column (15 cm x 4.6 mm), 5 µm particle size with the mobile phase composing of methanol: acetonitrile (70:30 v/v), delivered at flow rate 0.7 ml/min and UV detection wavelength at 250 nm.

Results: The retention time was observed at 2.718 min. The system suitability results were found to be within limits. The method was precise, with lower than 2 %RSD and the calibration curve was linear (r2=1) over a concentration range of 2.5-160 µg/ml. The detection and quantification limit was found to be 0.045 µg/ml and 0.15 µg/ml, respectively. Recovery of the drug was found between 100.09-100.19%. The assay of ropinirole hydrochloride in ROPITOR® and ROPARK® tablets were found to be 100.4 and 103.60 %, respectively. The forced degradation studies were carried out to demonstrate the specificity of the method by exposing the API under conditions of hydrolysis, oxidation, thermal and photolytic as per ICH Q1A(R2) guidelines.

Conclusion: The low coefficient of variation and agreeable recovery confirmed that the newly developed method could be employed for routine analysis of ropinirole hydrochloride in API and tablets.

Keywords: Ropinirole hydrochloride, RP-HPLC, Stability-indicating, Validation, Precision


Ropinirole hydrochloride (RH) is the hydrochloride salt form of ropinirole, a non-ergot dopamine agonist with antiparkinson property [1], acting as a substitute for dopamine, ropinirole acts as a D2, D3 and D4 dopamine receptor agonist with more affinity for D2. It is weakly active at the 5-HT2, and α2 receptors [2]. Chemically RH is a 4-[2-(dipropylamino) ethyl]-1,3-dihydro-2H-indol-2-one, hydrochloride (fig. 1). The molecular formula and weight of RH are C16H24N2O. HCl and 296.84 g/mol, respectively. The pKa and water solubility was found to be 10.17 and 133 mg/ml [3]. It is available in both conventional and extended-release tablet dosage form in the dose range from 0.25 mg up to 6 mg [4]. It is prescribed for the treatment of parkinson’s disease and restless legs syndrome [5].

Fig. 1: Chemical structure of RH (Molecular formula: C16H24N2O. HCl)

Literature survey reveals that different spectroscopic methods have been reported for the estimation of RH using UV-Visible spectrophotometry [6], liquid chromatography (HPLC) with UV detector [7-9], PDA detector [10], ECD detector [11], high performance thin layer chromatography [12, 13] and LC-ESI-MS/MS coupled to tandem mass spectrometry with electrospray ionization [14]. Among them, reported HPLC analytical methods in the literature for quantifying RH in API and its formulation has either had longer retention time or have tedious analytical procedures or not developed stability-indicating analytical procedure.

The objective of the present study was to develop a new, simple, rapid, precise, accurate and stability-indicating RP-HPLC to quantify RH in API and tablet dosage form together with its validation study [15, 16]. This work describes the validation parameters stated by the FDA [17] and ICH guidelines [18]. With the initiation of the ICH Q1A(R2) guidelines, requirements for the establishment of stability indicating methods have been ever more clearly mandated [19]. The guidelines explicitly require the conduct of forced degradation studies under a variety of conditions like hydrolysis (acid and alkaline), oxidation, photolytic and thermal, etc. and separation of drug from degradation products [20, 21].


Chemicals and reagents

A working reference standard (100.07 %) and API (100 %) of RH was obtained as a gift sample from Alembic Pharmaceuticals Ltd., Vadodara, Gujarat, India. HPLC grade methanol and acetonitrile solvents were purchased from Merck Specialities Pvt. Ltd. Mumbai, India. ROPITOR® 0.5 mg (Torrent Laboratories Pvt. Ltd.) and ROPARK® 0.5 mg (Sun Pharmaceuticals Industries Ltd.) tablets were procured from a local pharmacy. HPLC grade water was produced using a Millipore water purification system. AR grades of hydrochloric acid (HCl), hydrogen peroxide (H2O2) and sodium hydroxide (NaOH) used were purchased from S D Fine Chem Limited, Bengaluru. Class-A glassware was used throughout the experiments.

Instrumentation and chromatographic conditions

The instrument used and optimized chromatographic conditions for the determination of RH is given in table 1. Other equipment used was UV-Visible spectrophotometer (LAMBDA365, ParkinElmer Inc. USA), Analytical balance (Mettler Toledo, USA), Hot air oven and Digital ultrasonic water bath (Servewel instruments). A mixture of methanol: acetonitrile (70:30 v/v) was used as a mobile phase which was filtered through 0.45 µm finer porosity nylon membrane filter, degassed prior to use using a digital ultrasonic water bath.

Table 1: Instrumentation and chromatographic conditions

Parameter Instrument and optimized chromatographic conditions
Instrument High-performance liquid chromatography, Shimadzu-LC-20AD Prominence, Lab Solutions software was used for data acquisition and system suitability calculations.
Column Phenomenex, Gemini NX C18 Column (15 cm X 4.6 mm) 5 µm particle size
Detector UV Detector
Wavelength 250 nm
Injection volume 20 µl
Flow rate 0.7 ml/min
Mobile phase Methanol: acetonitrile (70:30 v/v)
Diluent Mobile phase
Mode of operation Isocratic elution

Preparation of standard and sample solution

The primary stock solution was prepared by dissolving API equivalent to 20 mg in 100 ml mobile phase, to get a concentration of 200 µg/ml. 1 ml of the primary stock solution was further diluted to 10 ml with the mobile phase to get a final concentration of 20 µg/ml (secondary stock solution). The absorbance of the secondary stock solution (20 µg/ml) was scanned in the range of 200 to 300 nm using a mobile phase as blank by UV-Visible spectrophotometer to select the detection wavelength. The sample solution was prepared by weighing twenty tablets from each product and their average weight was calculated, tablets were finely powdered. Tablet powder equivalent to 2 mg RH was weighed and transferred into a 100 ml volumetric flask containing 75 ml mobile phase, sonicated for 30 min with intermittent shaking to completely dissolve. Allowed to cool to room temperature and then made up the volume with the mobile phase to get a final sample concentration of 20 µg/ml. The above secondary stock solution and sample solutions were filtered through 0.45 µm nylon membrane (Millipore) syringe filter before injection.

Analysis of RH in marketed tablets

The developed method was used to estimate the total amount of drug present in commercially available tablets. The analysis was done by injecting API and sample drug solutions into the HPLC system (n=3) and the peak area count was recorded. Determine the amount of drug present in each marketed tablet samples.

Method validation

The developed method has been validated as per the USP and ICH guidelines includes system suitability, specificity, precision (system repeatability, method repeatability and intermediate precision) linearity, range, LOD and LOQ, stability of analytical solution, accuracy and robustness [17, 18, 23].

System suitability

The suitability of the system was tested by injecting the secondary stock solution into HPLC system as six replicates. The tailing factor for the RH peak from the first injection should be less than 2 and the column efficiency determined from the RH peak from the first injection should not be less than 2000 theoretical plates. The RSD for the mean peak area calculated from the six replicate injections of RH should be lower than 2 % [23].

Specificity and forced degradation studies

Specificity consisted of interference of blank (mobile phase). It was carried out by injecting six replicates of the mobile phase into the HPLC system to check the interference of any peak at the main peak of the analyte [22].

Forced degradation study was carried to give information about the degradation behavior of analyte in the presence of its degradation products during stress conditions. The API was subjected to hydrolysis (acid and alkali), oxidative, thermal and photolytic stress conditions [20, 21]. To assess the stress testing for acid hydrolysis, alkali hydrolysis, and oxidative studies by taking each 5 ml of primary stock solution (200 µg/ml) was transferred into three 50 ml volumetric flasks. Then the solution was mixed with 5 ml of 0.1N HCl, 5 ml of 0.1N NaOH and 5 ml of 3 % hydrogen peroxide was added to each volumetric flask. The prepared solutions were heated at 80 °C for 2 h in a boiling water bath, cooled to room temperature with intermittent shaking. These solutions were neutralized with an amount of acid or base equivalent to that of the previously added and then the volume was made up to the mark with mobile phase to get a concentration of the secondary stock solution. To assess the stress testing for thermal condition API was exposed to a temperature of 80 °C for 48 h in a hot air oven. 20 mg of API dried powder was weighed and transferred to a 100 ml volumetric flask containing 75 ml of mobile phase, dissolve and then volume is made up to the mark with the same, to get a concentration of 200 µg/ml, 1 ml of the above solution was further diluted to 10 ml with the mobile phase to get a final concentration of 20 µg/ml. Photolytic stress testing the secondary stock solution (20 µg/ml) was exposed to UV light (254 nm) for 72 h. Inject the resultant solution of all stress condition samples into the HPLC system, record the chromatograms to assess the degradation behavior of API during stress testing.


The precision of an analytical method is the closeness of agreement among individual test results when the method is applied repeatedly to multiple sampling of a homogenous sample. The precision of an analytical method is usually expressed in terms of RSD. In precision study system repeatability, method repeatability and intermediate precision have been carried out. The system and method repeatability were examined by analyzing API solution (20 µg/ml) in six replicates. %RSD of area counts of RH peak was calculated. Intermediate precision (Ruggedness) is carried out within the laboratory under different sets of conditions. Six replicates of API was injected into the HPLC system by different analysts, on different days (intraday-repeated for six replicates were injected at every h up to 12 h in the same day and interday-repeated six replicates for 3 d), on different instruments. %RSD for each condition was calculated.

Linearity, range

Linearity and range were established from the standard stock solution, a series of solutions were prepared at concentration levels ranging from 2.5 to 160 µg/ml of the standard solution. The peak area responses of solutions at all levels in six replicates were measured. The area count versus concentration data was treated by linear regression analysis and the linearity of response to RH was determined by calculating the correlation coefficient (acceptance criterion of correlation coefficient shall not be less than 0.997).


The LOD and LOQ were determined by visual evaluation by preparing the lowest dilution of API solution, injected into the HPLC system and the response obtained was recorded.

Stability of the analytical solution

The stability of the analytical solution was performed by preparing 20 µg/ml concentrations of API and sample (tablets) solutions. Both the solutions were kept at room temperature and analyzed at time intervals of 0, 24, 48 and 72 h. Six replicates of the API and sample solutions were injected into the HPLC system. The corresponding area counts for API and sample solutions were measured. Calculated the cumulative %RSD (acceptance criterion: cumulative %RSD shall not be more than 2).


Accuracy study, known concentration of the sample (10µg/ml) were taken separately into three set of nine volumetric flasks and spiked with known concentration of API at three different levels at 75 % (Level 1), 100 % (Level 2) and 125 % (Level 3) of sample concentration in triplicates. The prepared solutions were analyzed by injecting six replicates of each set in each level into the HPLC system and calculate the percentage amount of API recovered in spiked sample and %RSD in each level (acceptance criterion: %recovery shall be in the range of 98-102 and %RSD shall not be more than 2.0).


The robustness of an analytical method is used to measure its capacity to remain unaffected by small but deliberate variations in methods parameters and provides an indication of its reliability during normal usage. The robustness of the developed method was determined by changing the instrumental conditions flow rate (±0.07 ml/min), detection wavelength (±2 nm) and composition of the mobile phase (±5 v/v). System suitability parameters such as retention time, tailing factor, % RSD of area counts and theoretical plates of the standard solution was checked at each variable condition. The amount of drug recovered for each instrumental condition was calculated. The overall %RSD between the data and the amount of drug recovered at each variable condition (acceptance criterion: system suitability should pass, overall %RSD shall not be more than 2.0 and the amount of drug recovered should be less than±10 %).


HPLC method development and finalization

The maximum absorbance (λmax) of RH was found to be 250 nm in mobile phase using UV-Visible spectrophotometer. The spectrum is shown in fig. 2. This wavelength was chosen for the detection of RH. Several researchers earlier reported HPLC analytical methods for estimation of ropinirole hydrochloride in bulk and its pharmaceutical dosage form by varying the mobile phase composition, flow rate and stationary phase (column) to elute the RH. The RP-HPLC analytical method developed consists of a mobile phase phosphate buffer (pH 6) and acetonitrile (50:50 v/v), at a flow rate 0.5 ml/min stationary phase using C18 column 250 x 4.6 mm, 5 μm particle size in isocratic mode and the total run time was 15 min achieved the retention time of 4.867 min [8]. RP-HPLC method developed with mobile phase comprising of acetate buffer (0.05 mol glacial acetic acid, pH 3):acetonitrile in the ratio of 50:50 v/v, at a flow rate 1 ml/min using the column C18 Hypersil BDS (250 x 4.6 mm, 5 μm) at 250 nm, the analyte elutes at retention time of 4.037 min and running time is 14 min [7]. For the determination of impurities present in ropinirole tablets, the following HPLC analytical method was developed with retention time 26.80 min. Two sets of mobile phases were employed, A (mixture of potassium dihydrogen phosphate buffer (19.6 mmol):acetonitrile (98:2 v/v), adjust pH 7 using triethylamine) and B (acetonitrile) for enhancing the peak resolution. The flow rate was maintained during the analysis was 1 ml/min, the stationary phase used was Kromasil C8 (250 x 4.6 mm, 5 μm). The detector adopted was DAD detector and the mode of operation was in low-pressure gradient [10]. Another analytical method by RP-HPLC was developed to estimate simultaneously by ropinirole hydrochloride and its base by using a mobile phase acetonitrile: phosphate buffer (55:45 v/v) of pH 6 adjusted by adding 0.3 % triethanolamine solution. The flow rate was 1 ml/min. The stationary phase was Kromasil C18 (250 x 4 mm) to achieve retention time for ropinirole hydrochloride and its base ropinirole was 7.70 and 5.04 min, respectively [9]. Further one more method was developed for RH were in an ECD detector was adopted. The mobile phase comprises of methanol: 50 mmol sodium dihydrogen phosphate(10:90v/v), and its pH was adjusted with diethylamine to 4.5, the shorter stationary phase was Chromolith RP-18e (100 x 4.6 mm) to achieve 2.38 min as retention time and flow rate maintained was 2 ml/min [11]. To summarize the results with respect to the retention time and composition of the mobile phase from the above methods, retention time varies from 3.987 min to 26.80 min and with a shorter column length and high flow rate retention time was 2.85 min. Suggested that the developed methods were not economical since consumption of the mobile phase was directly proportional to retention time and as retention time was more in the above methods also lead less turnout of the samples makes these methods were not economical. The preparation of various mobile phases which were used in the above available methods includes weighing and use of buffers for adjustment of pH contributes to the inclusion of errors during the mobile phase preparation. The objectives of the present study were to develop RP-HPLC method to achieve shorter retention time, more turnout of the sample, less utilization of mobile phase and error-free procedure adopted to achieve economical method. The chromatographic method was developed by several trials were taken in order to finalize the chromatographic conditions. Various mobile phase composition with different pH was tried to elute the drug. The short retention time with a sharp peak of the analyte was dependent on the percentage of methanol and acetonitrile. Finally, the novel method was developed to quantitative estimation of RH in API and tablets consists of mobile phase methanol: acetonitrile (70:30 v/v) with Phenomenex, Gemini NX, C18 column (15 cm x 4.6 mm, 5 µm) stationary phase, at a flow rate of 0.7 ml/min with a short runtime of 7 min. The retention time was found to be 2.718 min and this above-developed method yields satisfactory separation, stable baseline and sharp symmetrical peak with satisfactory system suitability results. A typical chromatogram of RH and placebo obtained by using the above mentioned mobile phase is illustrated in fig. 3 and 4, respectively.

Fig. 2: UV-Visible spectra of RH in mobile phase (30 µg/ml), x-axis=Wavelength (nm) and y-axis=Absorbance

Fig. 3: HPLC Chromatogram and system suitability of RH at 250 nm (30 µg/ml)

Fig. 4: HPLC Chromatogram of placebo at 250 nm

Analysis of RH in marketed tablets

The amount of RH present in each product of ROPITOR® and ROPARK® marketed tablets were found to be 0.502 mg and 0.518 mg, respectively. This is equivalent to 100.4 to 103.6 percent of the label claim. The determined %assay of RH in both the tablets were found within the USP acceptance limits (90-110 %). The results show that there was no interference of excipients and impurities was observed in samples for the developed method.

Method validation

During the method validation study, known concentration of the standard solution was injected on different days. Using the LC solution software, retention time, theoretical plates and tailing factor for RH peak was recorded. %RSD for six replicates was calculated. The retention time, theoretical plates (N) and tailing factor for the RH from the API were found to be 2.718 min, 3646.257 and 1.310, respectively. The RSD for the mean peak area count calculated from the six replicates was found to be 0.097%. This indicates that the method is suitable. The above three system suitability parameters were met during the course of entire validation.

Specificity and forced degradation studies

The result of the specificity study indicates that there are not any co-eluting peaks from the blank (mobile phase) at the retention time of the analyte proved the specificity of the developed method. In forced degradation studies the RH was found to be degrading in acidic, alkaline and oxidative stress conditions. The RH solution heated with 0.1N HCl at 80 °C for 2 h showed 1.50 % degradation. Degradation peaks in acidic stress condition were observed at 3.63. 3.96 and 6.66 min. The RH solution heated with 0.1N NaOH at 80 °C for 2 h showed 3.60 % degradation. The degradation peaks in alkaline stress condition were observed at 4.12 and 4.48 min. The RH solution in oxidative stress condition (3 % H2O2 to heat at 80 °C for 2 h) was observed 3.2 % degradation. The degradation peaks in oxidative stress condition were observed at 3.66 and 4.13 min. During thermal degradation (exposed to 80 °C for 48 h) and photo degradation (exposed to UV light for 72 h), the chromatogram did not show the appearance of any degradation peak. Typical chro­matograms obtained for RH under different conditions are shown in fig. 5. From the forced degradation study, it can be concluded that RH peak obtained by analysis of API in all the stress condition was homogenous, pure and unchanged by the presence of its degradation products, confirming the stability indicating nature of the method. Hence, the developed method is able to quantify RH in the presence of its degradation products.


The HPLC system and developed method have an acceptable level of precision. The system and method repeatability were found to be precise as the %RSD of peak area counts for six replicates was found to be 0.349 and 0.532, respectively. In intermediate precision, the individual and overall %RSD under the different analytical procedure and laboratory conditions were found to be less than 2. The results reveal that the newly developed method was rugged.

The precision data are tabulated in table 2.

Fig. 5: HPLC Chromatograms showing forced degradation studies of RH under various stress conditions, x-axis=min and y-axis=peak area count (mV). Chromatograms showing API (A), acid degradation (B), alkaline degradation (C), oxidative degradation (D), thermal degradation (E) and photolytic degradation (F) studies

Table 2: Results of precision studies

Replicates System repeatability Method repeatability Intermediate precision
Peak Area Peak area Time interval (in h)
1 1112707 1134189 1
2 1121213 1137256 2
3 1120612 1132983 3
4 1119116 1137629 4
5 1118148 1147987 5
6 1124416 1145244 6
Mean 1119369 1139215
SD 3908 6062
%RSD 0.349 0.532

*Results obtained in different analysts by a different instrument, SD stands for standard deviation of six replicates.

Linearity, range

The regression equation from peak area count versus concentration data (fig. 6) obtained y=57411x+4867 and correlation coefficient (r2) was 1, indicating that the response is linear over the specified range of 2.5-160 µg/ml. The results are shown in table 3.

LOD, LOQ and stability of the analytical solution

The LOD and LOQ for RH were found to be 0.045 µg/ml and 0.15 µg/ml, respectively. It reveals that the developed method was more sensitive [24]. The cumulative %RSD of the API and sample solution was found to be 0.87 and 0.82, respectively, at room temperature. The determined cumulative %RSD of API and sample solution of RH was well within the limits of 2.0 %. It reveals that API and sample are stable in solution up to 72 h at room temperature.


Recovery studies of three samples in three concentration levels ranging from 75 to 125 % were determined. The individual and overall percentage recovery and %RSD of the API were found within the acceptance criteria, it was found that the percent recovery value of the API from the reanalyzed solution of the formulation was between 98 to 102. This indicates that the method is accurate and also reveals that commonly used excipients and additives in the tablet formulation were not interfering in the developed method. The results are given in table 4.

Fig. 6: Calibration curve of RH (y= 57411x+4867, r2= 1), (*n=6)

Table 3: Summary of regression analysis of the calibration curve

Parameters Results Acceptance Criteria
Linearity Range (µg/ml) 2.5-160 -
Regression equation (y=mx+c) y=57411x+4867 -
Correlation co-efficient (r2) 1.0 Not less than 0.997
Percentage curve fitting 99.9% Not less than 99%
Intercept (c) 4867 -
Slope (m) 57411 -

Table 4: Accuracy data



Sample conc. (µg/ml) Amt of std. added (µg/ml) Mean peak area Amt of std. recovered (µg)




% recovery



75 10 5 862928 5.000 100.01 100.17 0.470
10 5 865633 4.998 99.95
10 5 864490 5.025 100.55
100 10 10 1157061 10.113 101.13 100.19 0.531
10 10 1160680 10.760 99.76
10 10 1154523 10.069 100.69
125 10 15 1451613 14.934 99.56 100.09 0.135
10 15 1453342 15.264 100.76
10 15 1458129 14.993 99.95

Six replicates of 3 observations (n=3) in each level

Table 5: Robustness data

Parameters Normal condition* Flow rate(±10% ml/min) Wavelength(±2 nm) Mobile phase(±5 v/v)
0.63 0.77 248 252 65:35 75:25
Retention time (min) 2.874 3.437 2.975 2.972 2.984 2.758 2.644
Tailing factor 1.310 1.494 1.479 1.173 1.508 1.173 1.196
RSD (%) 0.532 0.433 0.121 0.179 0.295 0.696 0.616
Theoretical plate(#) 3646 2897 3127 2975 3614 3162 3098
Amount of drug recovered (%) 102.55 106.98 95.86 98.83 98.20 95.71 97.84

*Mobile phase: methanol: acetonitrile (70:30 v/v), column: Gemini NX C18-Phenomenex, detection wavelength: 250 nm, flow rate: 0.7 ml/min and injection volume: 20 μl.


With all the deliberate varied chromatographic conditions (flow rate, wavelength of detection and composition of the mobile phase). The results obtained were well within the limit, which proves the robustness of the method. The results of robustness data are given in table 5.


The present work, stability-indicating RP-HPLC method was developed for the quantitative estimation of RH in API and tablets is simple, rapid, economical, precise and accurate. The method has been validated and satisfactory results were found in all the tested validation parameters. The retention time was found to be 2.718 min due to this the method require less time, the consumption of the mobile phase is less. Preparation of the mobile phase involves no weighing procedures and use of buffers thereby reduces the human and instrumental error and increase the efficacy of the method as compared with the earlier reported HPLC-UV/DAD/ECD methods. The API and sample solution was stable up to 72 h at room temperature. The results of the stress testing reveal that the method is specific and there is no other co-eluting peak with the RH main peak. Hence, the developed method can be conveniently used for determining the quality control of RH in API and tablets.


The authors are thankful to M/s Alembic Pharmaceuticals Ltd, Vadodara, Gujarat, India for providing gift samples of working reference standard and API of RH with a certificate of analysis.


The first author conducted the experimental studies, data acquisition, data analysis, manuscript preparation and editing and the second author helped in manuscript preparation and editing. The third author designed and supervised the experimental work, data acquisition, data analysis, preparation of manuscript and critically reviewed the manuscript for final approval.


Declared none


  1. Sweetman SC. Martindale: the complete drug reference. 36th ed. London: Pharmaceutical Press; 2009.

  2. DeMaagd G, Philip A. Introduction to the pharmacotherapy of parkinson’s disease, with a focus on the use of dopaminergic agents. Pharm Ther 2015;40:590-600.

  3. Moursi NM, Elshafeey AH, Hamza MY, Elhadidy RM. Characterization and bioavailability study of ropinirole hydrochloride intranasal mucoadhesive thermoreversible in-situ gel. J Am Sci 2018;14:125-39.

  4. Singh ND, Banga AK. Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. J Drug Target 2013;21:354-66.

  5. Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, VanMeter S. A fixed-dose, dose–response study of ropinirole prolonged release in early stage parkinson's disease. Neurodegener Dis Manag 2017;7:49-59.

  6. Raghubabu K, Jagannadharao V, Ramu BK. Assay of ropinirole hydrochloride in pharmaceutical preparations by UV-visible spectrophotometry. Asian J Pharm Anal 2012;2:41-5.

  7. Samala A, Sowmya M, Sasikala M, Chatlapelli K. Development and validation of RP-HPLC method for the estimation of ropinirole hydrochloride in tablet dosage forms. J Chem Pharm Res 2014;6:1178-82.

  8. Sreekanth N, Rao B, Mukkanti K. RP-HPLC method development and validation of ropinirole hydrochloride in bulk and pharmaceutical dosage forms. Int J Pharm Pharm Sci 2009;1:186-92.

  9. Fuster J, Negro S, Salama A, Fernandez Carballido A, Marcianes P, Boeva L, et al. HPLC-UV method development and validation for the quantification of ropinirole in new PLGA multiparticulate systems: microspheres and nanoparticles. Int J Pharm 2015;491:310-7.

  10. Kakouris A, Samara V, Kalaskani A, Panderi I. Simultaneous determination of impurities in ropinirole tablets by an improved HPLC method coupled with diode array detection. Chromatographia 2014;77:447-57.

  11. Hefnawy M, Al-Majed A, Mohammed M, Attia S, Rizk M, El-Eryan RT. Development of a monolithic HPLC-ECD method for the determination of ropinirole HCl in mouse sera and dosage forms. Br J Pharm Res 2016;13:1-11.

  12. Bari SB, Bakhshi AR, Jain PS, Surana SJ. Development and validation of stability-indicating tlc-densitometric determination of ropinirole hydrochloride in bulk and pharmaceutical dosage form. Pharm Anal Acta 2011;2:1-7.

  13. Mustafa G, Ahuja A, Baboota S, Ali J. Box-behnken supported validation of stability-indicating high performance thin-layer chromatography method: an application in degradation kinetic profiling of ropinirole. Saudi Pharm J 2013;21:93-102.

  14. Bharathi DV, Jagadeesh B, Kumar SS, Lakshmi RN, Hotha KK, Naidu A, et al. Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/ml in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. Biomed Chromatogr 2009;23:557-62.

  15. Sindhusri M, Swetha T, Ramadevi A, Kumar AA. A novel rapid RP-HPLC method development and validation for the quantitative estimation of balofloxacin in tablets. Int J Pharm Pharm Sci 2014;7:319-22.

  16. Sureshbabu K, Nageshwara Rao M, Rambabu C. Forced degradation studies and RP-HPLC method validation for the determination of ceritinib in bulk and its pharmaceutical dosage form. Asian J Pharm Clin Res 2015;8:44-51.

  17. Guidance for Industry: Analytical procedures and methods validation for drugs and biologics. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research; 2014.

  18. International Conference on Harmonization (ICH), Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1); 2005.

  19. International Conference on Harmonization (ICH), Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A(R2); 2003.

  20. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs-a review. J Pharm Anal 2014;4:159-65.

  21. Jayaprakash R, Natesan SK. Stability indicating RP-HPLC method development and validation for the simultaneous determination of vildagliptin and metformin in pharmaceutical dosage form. Int J Pharm Pharm Sci 2017;9:150-7.

  22. Deshpande S, Farooqui M, Ganap G, Khadke V, Kayande DD. Development and validation of a gradient HPLC method for quantification of Edetate disodium in lyophilized injectable drug product. Int J Curr Pharm Res 2019;11:38-41.

  23. United States Pharmacopeia 40-National Formulary 35:Physical Tests. Chapter 621-Chromatography, System Suitability. Chapter 1225-Validation of Compendial Procedures, USP; 2017.

  24. Baje SI, Jyothi B, Madhavi N. RP-HPLC method for simultaneous estimation of ritonavir, ombitasvir and paritaprevir in tablet dosage forms and their stress degradation studies. Int J Appl Pharm 2019;11:193-210.